Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis
Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria. The trefoil factor family (TFF) is a family of three different peptides secreted by epithelial cells of the gastrointestinal tract in response to injury (Hoffman, 2004). Their presence has been implicated in reducing chemotherapy- and radiation-induced injury, both in preclinical studies (Beck et al., 2004) and in clinical trials (Peterson et al., 2009).
The company recently announced the completion of enrollment of 200 subjects with head and neck cancer receiving chemotherapy and radiation who will receive either AG013 (2.0 x 1011 CFU) or placebo administered three times a day over 7-9 weeks (depending on the subject’s treatment plan) (NCT03234465). This will be followed by a four-week follow-up phase with a long-term follow up until 12 months past the end of chemotherapy treatment. OM will be assessed at the start of chemotherapy treatment and will continue until the subject has completed the short-term follow up phase or until OM resolves (WHO score ≤ 1). The purpose of the long-term follow up is to assess whether AG013 has any effect on the tumor response to chemotherapy treatment. An overview of the trial is given below.
In September 2019, an interim safety analysis was conducted by a Data and Safety Monitoring Board (DSMB) from the first 100 patients enrolled in the study. Safety was evaluated based on treatment-emergent adverse events, vital signs, weight, physical examinations, clinical assessments, and the presence/absence of AG013 in the blood. The DSMB concluded there were no safety issues and that the trial could continue with no changes to the study protocol or further review. We anticipate top line results from the trial in the first half of 2020.
Poster on Phase 2 Trial of AG013 Presented at ESMO 2019
On September 30, 2019, Oragenics announced the presentation of a poster discussing the ongoing Phase 2 clinical trial of AG013 at the European Society for Medical Oncology (ESMO) Congress 2019 The poster can be accessed here.
The trial remains blinded, however an evaluation of blinded efficacy data (which included any patient with SOM after 1 week and those who received a cumulative dose of 55 Gy) demonstrated an overall SOM incidence of 47%, which is less than the expected rate of approximately two-thirds of head and neck cancer patients (Elting et al., 2007). In addition, the overall rate of SOM was reported in only 13.1% (110 of 842) evaluable visits. The following table lists the type and incidence of adverse events.
Publication Demonstrates First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog
On November 15, 2019, Oragenics announced a publication titled “Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization” was published in Journal of Peptide Science (Kirichenko et al., 2019). The purpose of this work was to expand the library of compounds derived from the lantibiotic compound mutacin 1140 (MU1140) in order to test for additional therapeutic applications for lantibiotics and look for broader spectrums of activity, including their potential use against Gram negative bacteria.
Novel Mechanism of Action for Lantibiotics
In June 2019, Oragenics announced the publication of research describing a novel mechanism of action for the company’s lantibiotic compounds in the journal Physical Chemistry Chemical Physics. The study examined the interaction of the lantibioitic compound MU1140 with lipid II along with the mechanism of membrane pore formation in Gram positive bacteria using molecular dynamics simulations. The results showed that MU1140-lipid II complexes form functional, water permeating membrane pores that ultimately results in the disruption of the bacterial membrane. This anti-microbial mechanism of action is in addition to the previously described mechanism of action of lipid II sequestration and disruption of cell membrane formation (Hasper et al., 2006; Smith et al., 2008). The results of these studies give greater insight into a novel mode of action of MU1140 and other lantibiotics and could lead to optimized lantibiotic variants with improved properties.
Background on Lantibiotics
Lantibiotics are a class of peptide antibiotics that are produced by certain Gram positive bacterial strains. The compounds range in size from 22 to 34 amino acids and typically go through a number of posttranslational modifications that results in novel serine and threonine derivatives, multiple types of sulfhydryl bonds, and the presence of the uncommon amino acids lanthionine (Lan) and B-methyllanthionine (MeLan), from which the lantibiotic name is derived. The compounds are classified based on their length, structure, and heat stability as Type A, Type B, Type IIa, and Type IIb.
Type A lantibiotics fall into two subcategories: compounds that are similar to nisin A (Gross et al., 1971) and those that are similar to mutacin 1140 (Smith et al., 2000). Nisin A is produced by Lactobacillus lactis while mutacin 1140 is produced by Streptococcus mutans. The structures of each of those compounds is shown below.
Oragenics lead lantibiotic development compound is OG716, a derivative of mutacin 1140. Earlier in 2019, new preclinical data was published for OG716 showing its activity in the Golden Syrian hamster model of Clostridium difficile associated disease (CDAD) (Pulse et al., 2019). As the following figure shows, all treatments using >18 mg/kg/day OG716 resulted in a statistically significant improvement in survival. The ED50 (which measures the concentration of a compound required for 50% maximal activity) was 23.85 mg/kg/day. On a molar basis, this compares quite favorably to vancomycin, which was dosed at 20 mg/kg/day. The ED50 of vancomycin was calculated as 13.8 μmole/kg/day compared to OG716 at 10.97 μmole/kg/day.
The researchers found a correlation between survival and both cecal CFU counts and levels of toxins A and B, the major virulence factors of C. difficile (Carter et al., 2010). The following figures show the correlation between A) titer levels of toxins A and B and survival and B) cecal CFU and survival. The data suggest that survival as a result of OG716 treatment is affected by the amounts of toxin and how much C. difficile is present in the ceca of infected animals.
Lastly, the researchers determined the maximum tolerated dose (MTD) of OG716, which included a pharmacokinetic (PK) analysis. Doses tested included 639 mg/kg/day, 1000 mg/kg/day, and 1,917 mg/kg/day (639 mg/kg dose 3 times). Following administration of those doses there were no deaths or significant clinical signs noted in any of the animals, except for a hunched posture noted in one animal following a single dose of OG716 at 639 mg/kg that lasted for only one day. PK analysis showed no prolonged systemic exposure of OG716 following doses at 1,000 and 1,917 mg/kg/day. Two animals from the 1,917 mg/kg/day group showed transient plasma elevations of OG716 of 10.3 ng/mL and 13.6 ng/mL. Of note, the lower limit of detection for that assay is 10 ng/mL Given that the molecular weight of OG716 (approximately 2.2 kDa) is larger than the maximum molecular weight for compounds to be able to pass freely through the gastrointestinal wall (approximately 500 Da), it is not surprising that there was very little systemic exposure of the drug even when dosed at very high levels.
Overall, these experiments confirm that OG716 has the potential to be an effective treatment for CDAD while also exhibiting an excellent safety profile. The company is continuing additional pre-IND activities, including animal toxicity studies and manufacturing additional material for stability studies. We believe the company will be in a position to file an IND in mid-2020.
On November 14, 2019, Oragenics filed form 10-Q with financial results for the third quarter of 2019. As expected, the company did not report any revenue during the third quarter of 2019. R&D expenses were $3.1 million for the third quarter of 2019 compared to $1.5 million for the third quarter of 2018. The increase was primarily due to increased costs associated with the company’s Phase 2 trial for AG013 and increased salary and insurance costs. G&A expenses were $0.9 million for the third quarter of 2019 compared to $1.2 million for the third quarter of 2018. The decrease was primarily due to decreased stock-based compensation. Net loss for the third quarter of 2019 was $3.8 million, or $0.08 per share, compared to a net loss of $4. million, or $0.35 per share, in the third quarter of 2019.
Oragenics exited the third quarter of 2019 with approximately $22.3 million in cash and cash equivalents. We estimate that the company has sufficient capital to fund operations into the fourth quarter of 2020. As of November 8, 2019, the company had approximately 46.1 million shares of common stock outstanding and when factoring in stock options and warrants a fully diluted share count of 78.8 million.
We value Oragenics using a probability adjusted discounted cash flow model that takes into account future revenues from AG013 and OG716. For modeling purposes, we anticipate AG013 entering a Phase 3 trial in 2020, an NDA filing in 2022, and approval in 2023 in the U.S. and Europe, with approval one year later in Japan. For OG716, we forecast for clinical trials to start in 2020, an NDA filing in 2024, and approval in 2025.
There are approximately 700,000 newly diagnosed cancer patients in the U.S. that could potentially develop OM, with another 1.3 million in the E.U. and 20,000 in Japan. Patients who develop OM currently have few treatment options available to them outside of palliative care. We believe that a successful treatment that both prevented the incidence of OM and also decreased the incidence of severe OM in those that develop it would be very appealing to oncologists. An effective OM therapy could also decrease rates of hospitalizations for patients suffering severe OM and limit the need to decrease or stop therapy. We use a very conservative 5% peak market share, an average length of use of 60 days, and a cost of $100/day in the U.S. ($70/day and $75/day for the E.U. and Japan, respectively) to arrive at peak worldwide sales of approximately $350 million. Using a 13% discount rate and a 40% chance of approval leads to a net present value of $210 million.
For OG716, we estimate peak market share of 10% of the approximately 500,000, 200,000, and 100,000 C. difficile infections each year in the U.S., E.U., and Japan, respectively. We estimate the cost of treatment of $3,000, $2,000, and $2,250 for the U.S., E.U., and Japan, respectively. This leads to peak worldwide revenues of approximately $275 million. Using a 13% discount rate and a 25% chance of approval leads to a net present value of $14 million.
Combining the net present values for AG013 and OG716 along with the company’s current cash position and potential cash from warrant exercises leads to a net present value for the company of $300 million. Dividing by the fully diluted share count of 78.8 million plus an additional 15 million shares for future dilution leads to a current value of approximately $3.00 per share.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.